Si kor loogu qaado faa'iidada horumarka togan ee maanta ee caafimaadka dadweynaha iyadoo la adeegsanayo oggolaanshaha Maamulka Cuntada iyo Dawooyinka (FDA) ee ka hortagga fayraska afka ee ugu horreeya ee lagu daweeyo COVID-19 suuqa, eMed wuxuu isu diyaarinayaa inuu daboolo baahidaas. Shirkaddu waxay ku ammaanaysaa FDA iyo Pfizer tallaabadan muhiimka ah ee dagaalka lagula jiro COVID-19.
Tijaabada-to-daawaynta ™, kobcinta guriga-guriga ee hadda jira, xal tijaabo ah oo la xaqiijiyay, ayaa loo sameeyay si loo fududeeyo bixinta degdegga ah ee daawaynta ka hortagga fayraska ee macaamiisheeda haddii ay tijaabiyaan cudurka COVID-19. Daawaynta cusub ee ka hortagga fayraska ee Pfizer ayaa waxtar u leh marka la bilaabo sida ugu dhakhsaha badan ee suurtogalka ah ka dib ogaanshaha COVID-19 iyo shan maalmood gudahooda ee calaamaduhu - madal waxa loogu talagalay inay xidho farqiga u dhexeeya ogaanshaha iyo daaweynta raaxada iyo badbaadada guriga macaamiisha. $25 dollar, macaamiilku waxa uu booqan karaa mareegaha shirkadda si loogu hago habka tijaabada guriga oo uu ku helo natiijooyin ansax ah 15 daqiiqo gudaheed taas oo keeni karta in loo qoro daawada fayraska afka haddii ay buuxiyaan shuruudaha loo baahan yahay.
Shirkaddu waxay sidoo kale diyaar u tahay inay dhamaystirto bixinta dawladda ee tijaabada bilaashka ah iyadoo bixinaysa natiijooyin la ansaxiyay. Tani waxay ka dhigan tahay in dadka Maraykanku ay dawladda ka heli karaan imtixaan bilaash ah oo ay isticmaalaan eMed si ay u helaan natiijooyin la xaqiijiyay oo loogu baahan yahay safarka, shaqada iyo wax ka badan.
MAXAA LAGU QAADAYAA MAQAALKAN:
- For $25 dollars, a consumer can visit the company website to be guided through the at-home testing process and receive validated results in 15 minutes that can lead to prescription for the oral antiviral if they meet the required criteria.
- The newly-approved antiviral therapeutic from Pfizer is most effective when initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset — the platform is designed to close the gap between diagnosis and treatment from the comfort and safety of the consumer’s home.
- To maximize the benefit of today’s positive development for population health with the Food and Drug Administration’s (FDA) authorization of the first oral antiviral for treatment of COVID-19 in the market, eMed is preparing to meet that need.
